Wire · opportunities
A Mass. biotech company had 'very encouraging' cancer trial results — then the funding disappeared
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 8 September 2026 · Fusion42 review
TScan Therapeutics, a Massachusetts-based clinical-stage biotech focused on cancer therapies, failed to secure funding for its promising Phase 3 trial in blood cancer, leading to a planned layoff of 75% of staff and a strategic shift to focus on solid tumors.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You must prepare for sudden funding loss even with promising clinical data as biotech capital can vanish, shifting your trial focus and forcing layoffs. Prioritise securing diverse partnerships earlier to maintain momentum and avoid costly restructures.
◆ Coverage
1 source · 8 Sep 2026
◆ Related on Wire
◆ Topics